newsfilter
← Latest News
PR Newswire·

Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026

  • Viking Therapeutics will present two posters at The Obesity Society's Annual Meeting, ObesityWeek, held November 14–17, 2026, in Washington, D.C.
  • The first poster details baseline characteristics from the Phase 3 VANQUISH-2 trial of subcutaneous VK2735 in adults with overweight & type 2 diabetes, presented by Jamy Ard on November 14, 2026.
  • The second poster covers the impact of subcutaneous VK2735 on obesity severity & cardiometabolic parameters from the Phase 2 VENTURE study, presented by Harold Bays on November 15, 2026.
  • VK2735 is a dual GLP-1 & GIP receptor agonist being developed in subcutaneous & oral formulations for metabolic disorders including obesity.
  • Viking is also advancing other programs including VK3019 (amylin receptor agonist), VK2809 (thyroid hormone receptor beta agonist), & VK0214 (for X-linked adrenoleukodystrophy).
  • The press release includes forward-looking statements subject to risks regarding clinical trial success, regulatory requirements, & timing of data reporting.
Company
Viking Therapeutics, Inc.
Keywords
Viking Therapeutics, Inc.